Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Cardinal Health sells MedSystems to private equity firm

This article was originally published in Clinica

  • News
  • Joseph Harvey  

Executive Summary

Cardinal Health has divested its enteral devices and surgical protection subsidiary MedSystems to healthcare and life sciences private equity firm Linden for an undisclosed fee. The subsidiary has been renamed Corpak MedSystems and will be headed by former MedSystems president Thomas Kuhn. Cardinal Health (Dublin, Ohio) said that despite MedSystems being a growing segment, it was not core to its clinical and medical products business. This deal sees Chicago, Illinois-based Linden gain a range of single-use feeding delivery devices and systems aimed towards serving hospital market. Cardinal Health originally gained the MedSystems business when it acquired respiratory care company Viasys Healthcare for $1.5bn in May last year (see Clinica No 1256, p 1).

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

See All
UsernamePublicRestriction

Register

MT043155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By